Compare Aurora Cannabis Inc (ACB) vs Amer Sports Inc (AS) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

Amer Sports (AS) trades at $36.84, up 2.02% today, with a bullish technical signal from moving averages and strong analyst consensus. The company reported robust Q1 2026 results, beating EPS estimates with $0.38 versus $0.31 expected, and raised full-year guidance. Revenue grew 32% year-over-year to $1.95 billion, driven by strength in Arc'teryx and Salomon brands.

Outlook is positive given earnings momentum and raised 2026 guidance, but risks include high valuation (P/E 45.2) and dependence on premium brand sustainability. The consensus price target of $58.67 implies significant upside, supported by 12 buy ratings. Investors should monitor Q2 2026 earnings on August 18 for continued growth validation.